Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to “Strong Sell”

Mineralys Therapeutics (NASDAQ:MLYS) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on MLYS. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. TD Cowen started coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating for the company. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen downgraded Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Mineralys Therapeutics currently has an average rating of “Hold” and an average price target of $49.33.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $25.64 on Thursday. The company’s fifty day simple moving average is $26.48 and its 200-day simple moving average is $27.54. The company has a quick ratio of 44.33, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.27 billion, a PE ratio of -6.05 and a beta of 0.68. Mineralys Therapeutics has a 12 month low of $14.16 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). Equities research analysts expect that Mineralys Therapeutics will post -3.89 EPS for the current fiscal year.

Insider Transactions at Mineralys Therapeutics

In other news, insider Eric Warren sold 104,124 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the transaction, the insider owned 38,400 shares in the company, valued at approximately $994,560. This trade represents a 73.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 9,890 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.81, for a total value of $235,480.90. Following the sale, the insider directly owned 57,095 shares of the company’s stock, valued at approximately $1,359,431.95. The trade was a 14.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 217,313 shares of company stock worth $5,624,488 over the last three months. Company insiders own 18.94% of the company’s stock.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. increased its holdings in Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after purchasing an additional 1,176,470 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Mineralys Therapeutics during the second quarter valued at about $158,832,000. Vanguard Group Inc. grew its holdings in shares of Mineralys Therapeutics by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company’s stock worth $121,676,000 after purchasing an additional 333,881 shares during the last quarter. State Street Corp increased its stake in shares of Mineralys Therapeutics by 144.4% in the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after buying an additional 1,881,976 shares during the period. Finally, Caligan Partners LP increased its stake in shares of Mineralys Therapeutics by 37.4% in the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock valued at $105,139,000 after buying an additional 755,302 shares during the period. 84.46% of the stock is currently owned by institutional investors.

Trending Headlines about Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.